Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 for Parkinson's Disease Dementia
NCT03774459Phase 2Completed
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Jul 2018
- Primary completion
- Sep 2020
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of blarcamesine in Parkinson's disease dementia (PDD), sponsored by Anavex Life Sciences Corp.. Started Jul 2018; status: completed.
02
Drugs
blarcamesine
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT03774459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03774459.